Polyglutamine (PolyQ) diseases: Genetics to treatments

Cell Transplantation

Volumn 23, Issue 4-5, 2014, Pages 441-458

  Fan, Hueng Chuen ^a   Ho, Li Ing ^b   Chi, Ching Shiang ^c   Chen, Shyi Jou ^a   Peng, Giia Sheun ^a   Chan, Tzu Min ^d,e   Lin, Shinn Zong ^d,e   Harn, Horng Jyh ^d  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY BEIGANG HOSPITAL   (Taiwan)

Author keywords

(SMAX1 SBMA); Cellular transplantation; Cytosine adenine guanine (CAG) repeats; Dentatorubral pallidoluysian atrophy (DRPLA); Huntington's disease (HD); Machado Joseph disease (MJD SCA3); Polyglutamine (polyQ); Spinal and bulbar muscular atrophy; Spinocerebellar ataxias (SCA); X linked

Indexed keywords

POLYGLUTAMINE; HTT PROTEIN, HUMAN; NERVE PROTEIN;

CLINICAL FEATURE; DENTATORUBROPALLIDOLUYSIAN ATROPHY; DRUG EFFICACY; EMBRYONIC STEM CELL; GENE THERAPY; GENETICS; HUMAN; HUNTINGTON CHOREA; KENNEDY DISEASE; MACHADO JOSEPH DISEASE; MESENCHYMAL STEM CELL; MOLECULAR GENETICS; NEURAL STEM CELL; NEUROIMAGING; NONHUMAN; PALLIATIVE THERAPY; PATHOGENESIS; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; SPINAL AND BULBAR MUSCULAR ATROPHY X LINKED 1; SPINOCEREBELLAR ATAXIA TYPE 1; SPINOCEREBELLAR ATAXIA TYPE 17; SPINOCEREBELLAR ATAXIA TYPE 2; SPINOCEREBELLAR ATAXIA TYPE 3; SPINOCEREBELLAR ATAXIA TYPE 6; SPINOCEREBELLAR ATAXIA TYPE 7; SPINOCEREBELLAR DEGENERATION; STEM CELL TRANSPLANTATION; TRINUCLEOTIDE REPEAT; UMBILICAL CORD BLOOD; CYTOLOGY; HUNTINGTON DISEASE; METABOLISM; MUSCULAR DISORDERS, ATROPHIC; MYOCLONIC EPILEPSIES, PROGRESSIVE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; SPINOCEREBELLAR ATAXIAS; STEM CELL;

GENETIC THERAPY; HUMANS; HUNTINGTON DISEASE; MAGNETIC RESONANCE IMAGING; MUSCULAR DISORDERS, ATROPHIC; MYOCLONIC EPILEPSIES, PROGRESSIVE; NERVE TISSUE PROTEINS; SPINOCEREBELLAR ATAXIAS; STEM CELL TRANSPLANTATION; STEM CELLS; TRINUCLEOTIDE REPEATS;

EID: 84900399340     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.3727/096368914X678454     Document Type: Review

References (236)

1. Adachi, H.; Waza, M.; Katsuno, M.; Tanaka, F.; Doyu, M.; Sobue, G. Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy. Neuropathol. Appl. Neurobiol. 33(2):135-151; 2007.
2. Almqvist, E. W.; Elterman, D. S.; MacLeod, P. M.; Hayden, M. R. High incidence rate and absent family histories in one quarter of patients newly diagnosed with Huntington disease in British Columbia. Clin. Genet. 60(3):198-205; 2001.
3. An, M. C.; Zhang, N.; Scott, G.; Montoro, D.; Wittkop, T.; Mooney, S.; Melov, S.; Ellerby, L. M. Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 11(2):253-263; 2012.
4. Antonini, G.; Gragnani, F.; Romaniello, A.; Pennisi, E. M.; Morino, S.; Ceschin, V.; Santoro, L.; Cruccu, G. Sensory involvement in spinal-bulbar muscular atrophy (Kennedy's disease). Muscle Nerve 23(2):252-258; 2000.
5. Armstrong, R. J.; Svendsen, C. N. Neural stem cells: From cell biology to cell replacement. Cell Transplant. 9(2):139-152; 2000.
6. Armstrong, R. J.; Watts, C.; Svendsen, C. N.; Dunnett, S. B.; Rosser, A. E. Survival, neuronal differentiation, and fiber outgrowth of propagated human neural precursor grafts in an animal model of Huntington's disease. Cell Transplant. 9(1):55-64; 2000.
7. Atsuta, N.; Watanabe, H.; Ito, M.; Banno, H.; Suzuki, K.; Katsuno, M.; Tanaka, F.; Tamakoshi, A.; Sobue, G. Natural history of spinal and bulbar muscular atrophy (SBMA): A study of 223 Japanese patients. Brain 129(Pt 6):1446-1455; 2006.
8. Aziz, N. A.; van der Burg, J. M.; Landwehrmeyer, G. B.; Brundin, P.; Stijnen, T.; Roos, R. A. Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 71(19):1506-1513; 2008.
9. Banisadr, G.; Skrzydelski, D.; Kitabgi, P.; Rostene, W.; Parsadaniantz, S. M. Highly regionalized distribution of stromal cell-derived factor-1/CXCL12 in adult rat brain: Constitutive expression in cholinergic, dopaminergic and vasopressinergic neurons. Eur. J. Neurosci. 18(6):1593-1606; 2003.
10. Barberi, T.; Klivenyi, P.; Calingasan, N. Y.; Lee, H.; Kawamata, H.; Loonam, K.; Perrier, A. L.; Bruses, J.; Rubio, M. E.; Topf, N.; Tabar, V.; Harrison, N. L.; Beal, M. F.; Moore, M. A.; Studer, L. Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nat. Biotechnol. 21(10):1200-1207; 2003.
11. Bates, G. Huntingtin aggregation and toxicity in Huntington's disease. Lancet 361(9369):1642-1644; 2003.
12. Battaglia, F.; Le Galudec, V.; Cossee, M.; Tranchant, C.; Warter, J. M.; Echaniz-Laguna, A. Kennedy's disease initially manifesting as an endocrine disorder. J. Clin. Neuromuscul. Dis. 4(4):165-167; 2003.
13. Bauer, P. O.; Nukina, N. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J. Neurochem. 110(6):1737-1765; 2009.
14. Bennett, E. J.; Shaler, T. A.; Woodman, B.; Ryu, K. Y.; Zaitseva, T. S.; Becker, C. H.; Bates, G. P.; Schulman, H.; Kopito, R. R. Global changes to the ubiquitin system in Huntington's disease. Nature 448(7154):704-708; 2007.
15. Benraiss, A.; Goldman, S. A. Cellular therapy and induced neuronal replacement for Huntington's disease. Neurotherapeutics 8(4):577-590; 2011.
16. Berke, S. J.; Chai, Y.; Marrs, G. L.; Wen, H.; Paulson, H. L. Defining the role of ubiquitin-interacting motifs in the polyglutamine disease protein, ataxin-3. J. Biol. Chem. 280(36):32026-32034; 2005.
17. Bettencourt, C.; Santos, C.; Kay, T.; Vasconcelos, J.; Lima, M. Analysis of segregation patterns in Machado-Joseph disease pedigrees. J. Hum. Genet. 53(10):920-923; 2008.
18. Borrell-Pages, M.; Canals, J. M.; Cordelieres, F. P.; Parker, J. A.; Pineda, J. R.; Grange, G.; Bryson, E. A.; Guillermier, M.; Hirsch, E.; Hantraye, P.; Cheetham, M. E.; Neri, C.; Alberch, J.; Brouillet, E.; Saudou, F.; Humbert, S. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J. Clin. Invest. 116(5):1410-1424; 2006.
19. Bortvedt, S. F.; McLear, J. A.; Messer, A.; Ahern-Rindell, A. J.; Wolfgang, W. J. Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease. Neurobiol. Dis. 40(1):130-134; 2010.
20. Burke, J. R.; Ikeuchi, T.; Koide, R.; Tsuji, S.; Yamada, M.; Pericak-Vance, M. A.; Vance, J. M. Dentatorubralpallidoluysian atrophy and Haw River syndrome. Lancet 344(8938):1711-1712; 1994.
21. Butler, D. C.; McLear, J. A.; Messer, A. Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins. Prog. Neurobiol. 97(2):190-204; 2012.
22. Cancel, G.; Durr, A.; Didierjean, O.; Imbert, G.; Burk, K.; Lezin, A.; Belal, S.; Benomar, A.; Abada-Bendib, M.; Vial, C.; Guimaraes, J.; Chneiweiss, H.; Stevanin, G.; Yvert, G.; Abbas, N.; Saudou, F.; Lebre, A. S.; Yahyaoui, M.; Hentati, F.; Vernant, J. C.; Klockgether, T.; Mandel, J. L.; Agid, Y.; Brice, A. Molecular and clinical correlations in spinocerebellar ataxia 2: A study of 32 families. Hum. Mol. Genet. 6(5):709-715; 1997.
23. Cemal, C. K.; Carroll, C. J.; Lawrence, L.; Lowrie, M. B.; Ruddle, P.; Al-Mahdawi, S.; King, R. H.; Pook, M. A.; Huxley, C.; Chamberlain, S. YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit. Hum. Mol. Genet. 11(9):1075-1094; 2002.
24. Cha, J. H. Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 23(9):387-392; 2000.
25. Chafekar, S. M.; Duennwald, M. L. Impaired heat shock response in cells expressing full-length polyglutamineexpanded huntingtin. PLoS One 7(5):e37929; 2012.
26. Chahin, N.; Sorenson, E. J. Serum creatine kinase levels in spinobulbar muscular atrophy and amyotrophic lateral sclerosis. Muscle Nerve 40(1):126-129; 2009.
27. Chang, C. M.; Yu, Y. L.; Fong, K. Y.; Wong, M. T.; Chan, Y. W.; Ng, T. H.; Leung, C. M.; Chan, V. Huntington's disease in Hong Kong Chinese: Epidemiology and clinical picture. Clin. Exp. Neurol. 31:43-51; 1994.
28. Chang, Y. K.; Chen, M. H.; Chiang, Y. H.; Chen, Y. F.; Ma, W. H.; Tseng, C. Y.; Soong, B. W.; Ho, J. H.; Lee, O. K. Mesenchymal stem cell transplantation ameliorates motor function deterioration of spinocerebellar ataxia by rescuing cerebellar Purkinje cells. J. Biomed. Sci. 18:54; 2011.
29. Chen, J.; Zhang, Z. G.; Li, Y.; Wang, L.; Xu, Y. X.; Gautam, S. C.; Lu, M.; Zhu, Z.; Chopp, M. Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats. Circ. Res. 92(6):692-699; 2003.
30. Chen, Y. Y.; Lai, C. H. Nationwide population-based epidemiologic study of Huntington's Disease in Taiwan. Neuroepidemiology 35(4):250-254; 2010.
31. Chevalier-Larsen, E. S.; O'Brien, C. J.; Wang, H.; Jenkins, S. C.; Holder, L.; Lieberman, A. P.; Merry, D. E. Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J. Neurosci. 24(20):4778-4786; 2004.
32. Chintawar, S.; Hourez, R.; Ravella, A.; Gall, D.; Orduz, D.; Rai, M.; Bishop, D. P.; Geuna, S.; Schiffmann, S. N.; Pandolfo, M. Grafting neural precursor cells promotes functional recovery in an SCA1 mouse model. J. Neurosci. 29(42):13126-13135; 2009.
33. Ciechanover, A.; Brundin, P. The ubiquitin proteasome system in neurodegenerative diseases: Sometimes the chicken, sometimes the egg. Neuron 40(2):427-446; 2003.
34. Craig, K.; Keers, S. M.; Walls, T. J.; Curtis, A.; Chinnery, P. F. Minimum prevalence of spinocerebellar ataxia 17 in the north east of England. J. Neurol. Sci. 239(1):105-109; 2005.
35. David, G.; Durr, A.; Stevanin, G.; Cancel, G.; Abbas, N.; Benomar, A.; Belal, S.; Lebre, A. S.; Abada-Bendib, M.; Grid, D.; Holmberg, M.; Yahyaoui, M.; Hentati, F.; Chkili, T.; Agid, Y.; Brice, A. Molecular and clinical correlations in autosomal dominant cerebellar ataxia with progressive macular dystrophy (SCA7). Hum. Mol. Genet. 7(2):165-170; 1998.
36. Dejager, S.; Bry-Gauillard, H.; Bruckert, E.; Eymard, B.; Salachas, F.; LeGuern, E.; Tardieu, S.; Chadarevian, R.; Giral, P.; Turpin, G. A comprehensive endocrine description of Kennedy's disease revealing androgen insensitivity linked to CAG repeat length. J. Clin. Endocrinol. Metab. 87(8):3893-3901; 2002.
37. Di Domenico, C.; Villani, G. R.; Di Napoli, D.; Reyero, E. G.; Lombardo, A.; Naldini, L.; Di Natale, P. Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector. Hum. Gene Ther. 16(1):81-90; 2005.
38. Dimos, J. T.; Rodolfa, K. T.; Niakan, K. K.; Weisenthal, L. M.; Mitsumoto, H.; Chung, W.; Croft, G. F.; Saphier, G.; Leibel, R.; Goland, R.; Wichterle, H.; Henderson, C. E.; Eggan, K. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 321(5893):1218-1221; 2008.
39. Ding, S. W.; Voinnet, O. Antiviral immunity directed by small RNAs. Cell 130(3):413-426; 2007.
40. Doss-Pepe, E. W.; Stenroos, E. S.; Johnson, W. G.; Madura, K. Ataxin-3 interactions with rad23 and valosin-containing protein and its associations with ubiquitin chains and the proteasome are consistent with a role in ubiquitin-mediated proteolysis. Mol. Cell. Biol. 23(18):6469-6483; 2003.
41. Doyu, M.; Sobue, G.; Mukai, E.; Kachi, T.; Yasuda, T.; Mitsuma, T.; Takahashi, A. Severity of X-linked recessive bulbospinal neuronopathy correlates with size of the tandem CAG repeat in androgen receptor gene. Ann. Neurol. 32(5):707-710; 1992.
42. Drouet, V.; Perrin, V.; Hassig, R.; Dufour, N.; Auregan, G.; Alves, S.; Bonvento, G.; Brouillet, E.; Luthi-Carter, R.; Hantraye, P.; Deglon, N. Sustained effects of nonallelespecific Huntingtin silencing. Ann. Neurol. 65(3):276-285; 2009.
43. Durr, A. Autosomal dominant cerebellar ataxias: Polyglutamine expansions and beyond. Lancet Neurol. 9(9): 885-894; 2010.
44. Duyao, M. P.; Auerbach, A. B.; Ryan, A.; Persichetti, F.; Barnes, G. T.; McNeil, S. M.; Ge, P.; Vonsattel, J. P.; Gusella, J. F.; Joyner, A. L. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 269(5222):407-410; 1995.
45. Ebert, A. D.; Yu, J.; Rose, Jr., F. F.; Mattis, V. B.; Lorson, C. L.; Thomson, J. A.; Svendsen, C. N. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 457(7227):277-280; 2009.
46. Emgard, M.; Hallin, U.; Karlsson, J.; Bahr, B. A.; Brundin, P.; Blomgren, K. Both apoptosis and necrosis occur early after intracerebral grafting of ventral mesencephalic tissue: A role for protease activation. J. Neurochem. 86(5):1223-1232; 2003.
47. Englund, U.; Bjorklund, A.; Wictorin, K.; Lindvall, O.; Kokaia, M. Grafted neural stem cells develop into functional pyramidal neurons and integrate into host cortical circuitry. Proc. Natl. Acad. Sci. USA 99(26):17089-17094; 2002.
48. Evers, M. M.; Pepers, B. A.; van Deutekom, J. C.; Mulders, S. A.; den Dunnen, J. T.; Aartsma-Rus, A.; van Ommen, G. J.; van Roon-Mom, W. M. Targeting several CAG expansion diseases by a single antisense oligonucleotide. PLoS One 6(9):e24308; 2011.
49. Ferrante, M. A.; Wilbourn, A. J. The characteristic electrodiagnostic features of Kennedy's disease. Muscle Nerve 20(3):323-329; 1997.
50. Finsterer, J. Perspectives of Kennedy's disease. J. Neurol. Sci. 298(1-2):1-10; 2010.
51. Fischbeck, K. H. Kennedy disease. J. Inherit. Metab. Dis. 20(2):152-158; 1997.
52. Fouillard, L.; Chapel, A.; Bories, D.; Bouchet, S.; Costa, J. M.; Rouard, H.; Herve, P.; Gourmelon, P.; Thierry, D.; Lopez, M.; Gorin, N. C. Infusion of allogeneic-related HLA mismatched mesenchymal stem cells for the treatment of incomplete engraftment following autologous haematopoietic stem cell transplantation. Leukemia 21(3): 568-570; 2007.
53. Fricker, R. A.; Carpenter, M. K.; Winkler, C.; Greco, C.; Gates, M. A.; Bjorklund, A. Site-specific migration and neuronal differentiation of human neural progenitor cells after transplantation in the adult rat brain. J. Neurosci. 19(14):5990-6005; 1999.
54. Friedman, M. J.; Li, S.; Li, X. J. Activation of gene transcription by heat shock protein 27 may contribute to its neuronal protection. J. Biol. Chem. 284(41):27944-27951; 2009.
55. Friedman, M. J.; Shah, A. G.; Fang, Z. H.; Ward, E. G.; Warren, S. T.; Li, S.; Li, X. J. Polyglutamine domain modulates the TBP-TFIIB interaction: Implications for its normal function and neurodegeneration. Nat. Neurosci. 10(12):1519-1528; 2007.
56. Friedman, M. J.; Wang, C. E.; Li, X. J.; Li, S. Polyglutamine expansion reduces the association of TATA-binding protein with DNA and induces DNA binding-independent neurotoxicity. J. Biol. Chem. 283(13):8283-8290; 2008.
57. Gatchel, J. R.; Zoghbi, H. Y. Diseases of unstable repeat expansion: Mechanisms and common principles. Nat. Rev. Genet. 6(10):743-755; 2005.
58. Gierga, K.; Schelhaas, H. J.; Brunt, E. R.; Seidel, K.; Scherzed, W.; Egensperger, R.; de Vos, R. A.; den Dunnen, W.; Ippel, P. F.; Petrasch-Parwez, E.; Deller, T.; Schols, L.; Rub, U. Spinocerebellar ataxia type 6 (SCA6): Neurodegeneration goes beyond the known brain predilection sites. Neuropathol. Appl. Neurobiol. 35(5):515-527; 2009.
59. Gilman, S. The spinocerebellar ataxias. Clin. Neuropharmacol. 23(6):296-303; 2000.
60. Goti, D.; Katzen, S. M.; Mez, J.; Kurtis, N.; Kiluk, J.; Ben-Haiem, L.; Jenkins, N. A.; Copeland, N. G.; Kakizuka, A.; Sharp, A. H.; Ross, C. A.; Mouton, P. R.; Colomer, V. A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. J. Neurosci. 24(45):10266-10279; 2004.
61. Guidetti, D.; Sabadini, R.; Ferlini, A.; Torrente, I. Epidemiological survey of X-linked bulbar and spinal muscular atrophy, or Kennedy disease, in the province of Reggio Emilia, Italy. Eur. J. Epidemiol. 17(6):587-591; 2001.
62. Hagenah, J. M.; Zuhlke, C.; Hellenbroich, Y.; Heide, W.; Klein, C. Focal dystonia as a presenting sign of spinocerebellar ataxia 17. Mov. Disord. 19(2):217-220; 2004.
63. Hanajima, R.; Terao, Y.; Nakatani-Enomoto, S.; Hamada, M.; Yugeta, A.; Matsumoto, H.; Yamamoto, T.; Tsuji, S.; Ugawa, Y. Postural tremor in X-linked spinal and bulbar muscular atrophy. Mov. Disord. 24(14):2063-2069; 2009.
64. Harding, A. E.; Thomas, P. K.; Baraitser, M.; Bradbury, P. G.; Morgan-Hughes, J. A.; Ponsford, J. R. X-linked recessive bulbospinal neuronopathy: A report of ten cases. J. Neurol. Neurosurg. Psychiatry 45(11):1012-1019; 1982.
65. Harjes, P.; Wanker, E. E. The hunt for huntingtin function: Interaction partners tell many different stories. Trends Biochem. Sci 28(8):425-433; 2003.
66. Harper, S. Q.; Staber, P. D.; Beck, C. R.; Fineberg, S. K.; Stein, C.; Ochoa, D.; Davidson, B. L. Optimization of feline immunodeficiency virus vectors for RNA interference. J. Virol. 80(19):9371-9380; 2006.
67. Hatano, T.; Okuma, Y.; Iijima, M.; Fujishima, K.; Goto, K.; Mizuno, Y. Cervical dystonia in dentatorubral-pallidoluysian atrophy. Acta Neurol. Scand. 108(4):287-289; 2003.
68. Hayashi, Y.; Kakita, A.; Yamada, M.; Koide, R.; Igarashi, S.; Takano, H.; Ikeuchi, T.; Wakabayashi, K.; Egawa, S.; Tsuji, S.; Takahashi, H. Hereditary dentatorubral-pallidoluysian atrophy: Detection of widespread ubiquitinated neuronal and glial intranuclear inclusions in the brain. Acta Neuropathol. 96(6):547-552; 1998.
69. Hellmann, M. A.; Panet, H.; Barhum, Y.; Melamed, E.; Offen, D. Increased survival and migration of engrafted mesenchymal bone marrow stem cells in 6-hydroxydopaminelesioned rodents. Neurosci. Lett. 395(2):124-128; 2006.
70. Helmlinger, D.; Hardy, S.; Abou-Sleymane, G.; Eberlin, A.; Bowman, A. B.; Gansmuller, A.; Picaud, S.; Zoghbi, H. Y.; Trottier, Y.; Tora, L.; Devys, D. Glutamineexpanded ataxin-7 alters TFTC/STAGA recruitment and chromatin structure leading to photoreceptor dysfunction. PLoS. Biol. 14(3):e67; 2006.
71. Helmlinger, D.; Hardy, S.; Sasorith, S.; Klein, F.; Robert, F.; Weber, C.; Miguet, L.; Potier, N.; Van-Dorsselaer, A.; Wurtz, J. M.; Mandel, J. L.; Tora, L.; Devys, D. Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes. Hum. Mol. Genet. 13(12):1257-1265; 2004.
72. Higashihara, M.; Sonoo, M.; Yamamoto, T.; Nagashima, Y.; Uesugi, H.; Terao, Y.; Ugawa, Y.; Stalberg, E.; Tsuji, S. Evaluation of spinal and bulbar muscular atrophy by the clustering index method. Muscle Nerve 44(4):539-546; 2011.
73. Hochfeld, W. E.; Lee, S.; Rubinsztein, D. C. Therapeutic induction of autophagy to modulate neurodegenerative disease progression. Acta Pharmacol. Sin. 34(5):600-604; 2013.
74. Hodgson, J. G.; Agopyan, N.; Gutekunst, C. A.; Leavitt, B. R.; LePiane, F.; Singaraja, R.; Smith, D. J.; Bissada, N.; McCutcheon, K.; Nasir, J.; Jamot, L.; Li, X. J.; Stevens, M. E.; Rosemond, E.; Roder, J. C.; Phillips, A. G.; Rubin, E. M.; Hersch, S. M.; Hayden, M. R. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23(1):181-192; 1999.
75. Holmberg, M.; Duyckaerts, C.; Durr, A.; Cancel, G.; Gourfinkel-An, I.; Damier, P.; Faucheux, B.; Trottier, Y.; Hirsch, E. C.; Agid, Y.; Brice, A. Spinocerebellar ataxia type 7 (SCA7): A neurodegenerative disorder with neuronal intranuclear inclusions. Hum. Mol. Genet. 7(5):913-918; 1998.
76. Hsieh, M.; Lin, S. J.; Chen, J. F.; Lin, H. M.; Hsiao, K. M.; Li, S. Y.; Li, C.; Tsai, C. J. Identification of the spinocerebellar ataxia type 7 mutation in Taiwan: Application of PCRbased Southern blot. J. Neurol. 247(8):623-629; 2000.
77. Huang, C. C.; Faber, P. W.; Persichetti, F.; Mittal, V.; Vonsattel, J. P.; MacDonald, M. E.; Gusella, J. F. Amyloid formation by mutant huntingtin: Threshold, progressivity, and recruitment of normal polyglutamine proteins. Somat. Cell Mol. Genet. 24(4):217-233; 1998.
78. Huynh, D. P.; Del Bigio, M. R.; Ho, D. H.; Pulst, S. M. Expression of ataxin-2 in brains from normal individuals and patients with Alzheimer's disease and spinocerebellar ataxia 2. Ann. Neurol. 45(2):232-241; 1999.
79. Ihara, Y.; Namba, R.; Nobukuni, K.; Kawai, K.; Kuroda, S. [Relation between cerebral white matter damage on CT and MRI and clinical data in DRPLA (pseudo-Huntington form)]. Rinsho Shinkeigaku 31(8):815-820; 1991.
80. Ikeda, H.; Yamaguchi, M.; Sugai, S.; Aze, Y.; Narumiya, S.; Kakizuka, A. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat. Genet. 13(2):196-202; 1996.
81. Ikeuchi, T.; Onodera, O.; Oyake, M.; Koide, R.; Tanaka, H.; Tsuji, S. Dentatorubral-pallidoluysian atrophy (DRPLA): Close correlation of CAG repeat expansions with the wide spectrum of clinical presentations and prominent anticipation. Semin. Cell Biol. 16(1):37-44; 1995.
82. Ishikawa, K.; Mizusawa, H. [Spinocerebellar ataxia type 6]. Clin. Calcium 11(11):1451-1455; 2001.
83. Ishikawa, K.; Owada, K.; Ishida, K.; Fujigasaki, H.; Shun, L. M.; Tsunemi, T.; Ohkoshi, N.; Toru, S.; Mizutani, T.; Hayashi, M.; Arai, N.; Hasegawa, K.; Kawanami, T.; Kato, T.; Makifuchi, T.; Shoji, S.; Tanabe, T.; Mizusawa, H. Cytoplasmic and nuclear polyglutamine aggregates in SCA6 Purkinje cells. Neurology 56(12):1753-1756; 2001.
84. Ishikawa, K.; Watanabe, M.; Yoshizawa, K.; Fujita, T.; Iwamoto, H.; Yoshizawa, T.; Harada, K.; Nakamagoe, K.; Komatsuzaki, Y.; Satoh, A.; Doi, M.; Ogata, T.; Kanazawa, I.; Shoji, S.; Mizusawa, H. Clinical, neuropathological, and molecular study in two families with spinocerebellar ataxia type 6 (SCA6). J. Neurol. Neurosurg. Psychiatry 67(1):86-89; 1999.
85. Jimenez-Sanchez, M.; Thomson, F.; Zavodszky, E.; Rubinsztein, D. C. Autophagy and polyglutamine diseases. Prog. Neurobiol. 97(2):67-82; 2012.
86. Joers, V. L.; Emborg, M. E. Preclinical assessment of stem cell therapies for neurological diseases. ILAR J. 51(1): 24-41; 2009.
87. Jones, J.; Jaramillo-Merchan, J.; Bueno, C.; Pastor, D.; Viso-Leon, M.; Martinez, S. Mesenchymal stem cells rescue Purkinje cells and improve motor functions in a mouse model of cerebellar ataxia. Neurobiol. Dis. 40(2): 415-423; 2010.
88. Jung, B. C.; Choi, S. I.; Du, A. X.; Cuzzocreo, J. L.; Ying, H. S.; Landman, B. A.; Perlman, S. L.; Baloh, R. W.; Zee, D. S.; Toga, A. W.; Prince, J. L.; Ying, S. H. MRI shows a region-specific pattern of atrophy in spinocerebellar ataxia type 2. Cerebellum 11(1):272-279; 2012.
89. Kassubek, J.; Juengling, F. D.; Sperfeld, A. D. Widespread white matter changes in Kennedy disease: A voxel based morphometry study. J. Neurol. Neurosurg. Psychiatry 78(11):1209-1212; 2007.
90. Katsuno, M.; Adachi, H.; Doyu, M.; Minamiyama, M.; Sang, C.; Kobayashi, Y.; Inukai, A.; Sobue, G. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat. Med. 9(6):768-773; 2003.
91. Katsuno, M.; Adachi, H.; Kume, A.; Li, M.; Nakagomi, Y.; Niwa, H.; Sang, C.; Kobayashi, Y.; Doyu, M.; Sobue, G. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35(5):843-854; 2002.
92. Katsuno, M.; Adachi, H.; Minamiyama, M.; Waza, M.; Doi, H.; Kondo, N.; Mizoguchi, H.; Nitta, A.; Yamada, K.; Banno, H.; Suzuki, K.; Tanaka, F.; Sobue, G. Disrupted transforming growth factor-beta signaling in spinal and bulbar muscular atrophy. J. Neurosci. 30(16):5702-5712; 2010.
93. Katsuno, M.; Sang, C.; Adachi, H.; Minamiyama, M.; Waza, M.; Tanaka, F.; Doyu, M.; Sobue, G. Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proc. Natl. Acad. Sci. USA 102(46):16801-16806; 2005.
94. Katsuno, M.; Tanaka, F.; Adachi, H.; Banno, H.; Suzuki, K.; Watanabe, H.; Sobue, G. Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA). Prog. Neurobiol. 99(3):246-256; 2012.
95. Kennedy, W. R.; Alter, M.; Sung, J. H. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sexlinked recessive trait. Neurology 18(7):671-680; 1968.
96. Kim, J. H.; Auerbach, J. M.; Rodriguez-Gomez, J. A.; Velasco, I.; Gavin, D.; Lumelsky, N.; Lee, S. H.; Nguyen, J.; Sanchez-Pernaute, R.; Bankiewicz, K.; McKay, R. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 418(6893):50-56; 2002.
97. Klement, I. A.; Skinner, P. J.; Kaytor, M. D.; Yi, H.; Hersch, S. M.; Clark, H. B.; Zoghbi, H. Y.; Orr, H. T. Ataxin-1 nuclear localization and aggregation: Role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 95(1):41-53; 1998.
98. Klockgether, T.; Skalej, M.; Wedekind, D.; Luft, A. R.; Welte, D.; Schulz, J. B.; Abele, M.; Burk, K.; Laccone, F.; Brice, A.; Dichgans, J. Autosomal dominant cerebellar ataxia type I. MRI-based volumetry of posterior fossa structures and basal ganglia in spinocerebellar ataxia types 1, 2 and 3. Brain 121(Pt 9):1687-1693; 1998.
99. Koch, P.; Breuer, P.; Peitz, M.; Jungverdorben, J.; Kesavan, J.; Poppe, D.; Doerr, J.; Ladewig, J.; Mertens, J.; Tuting, T.; Hoffmann, P.; Klockgether, T.; Evert, B. O.; Wullner, U.; Brustle, O. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature 480(7378):543-546; 2011.
100. Koeppen, A. H. The pathogenesis of spinocerebellar ataxia. Cerebellum 4(1):62-73; 2005.
101. Koide, R.; Kobayashi, S.; Shimohata, T.; Ikeuchi, T.; Maruyama, M.; Saito, M.; Yamada, M.; Takahashi, H.; Tsuji, S. A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: A new polyglutamine disease? Hum. Mol. Genet. 8(11):2047-2053; 1999.
102. Koide, R.; Onodera, O.; Ikeuchi, T.; Kondo, R.; Tanaka, H.; Tokiguchi, S.; Tomoda, A.; Miike, T.; Isa, F.; Beppu, H.; Shimizu, N.; Watanabe, Y.; Horikawa, Y.; Shimohata, T.; Hirota, K.; Ishikawa, A.; Tsuji, S. Atrophy of the cerebellum and brainstem in dentatorubral pallidoluysian atrophy. Influence of CAG repeat size on MRI findings. Neurology 49(6):1605-1612; 1997.
103. Kokmen, E.; Ozekmekci, F. S.; Beard, C. M.; O'Brien, P. C.; Kurland, L. T. Incidence and prevalence of Huntington's disease in Olmsted County, Minnesota (1950 through 1989). Arch. Neurol. 51(7):696-698; 1994.
104. Komure, O.; Sano, A.; Nishino, N.; Yamauchi, N.; Ueno, S.; Kondoh, K.; Sano, N.; Takahashi, M.; Murayama, N.; Kondo, I.; Nagafuchi, S.; Yamada, M.; Kanazawa, I. DNA analysis in hereditary dentatorubral-pallidoluysian atrophy: Correlation between CAG repeat length and phenotypic variation and the molecular basis of anticipation. Neurology 45(1):143-149; 1995.
105. Lasek, K.; Lencer, R.; Gaser, C.; Hagenah, J.; Walter, U.; Wolters, A.; Kock, N.; Steinlechner, S.; Nagel, M.; Zuhlke, C.; Nitschke, M. F.; Brockmann, K.; Klein, C.; Rolfs, A.; Binkofski, F. Morphological basis for the spectrum of clinical deficits in spinocerebellar ataxia 17 (SCA17). Brain 129(Pt 9):2341-2352; 2006.
106. La Spada, A. R.; Fu, Y. H.; Sopher, B. L.; Libby, R. T.; Wang, X.; Li, L. Y.; Einum, D. D.; Huang, J.; Possin, D. E.; Smith, A. C.; Martinez, R. A.; Koszdin, K. L.; Treuting, P. M.; Ware, C. B.; Hurley, J. B.; Ptacek, L. J.; Chen, S. Polyglutamine-expanded ataxin-7 antagonizes CRX function and induces cone-rod dystrophy in a mouse model of SCA7. Neuron 31(6):913-927; 2001.
107. La Spada, A. R.; Taylor, J. P. Polyglutamines placed into context. Neuron 38(5):681-684; 2003.
108. La Spada, A. R.; Wilson, E. M.; Lubahn, D. B.; Harding, A. E.; Fischbeck, K. H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352(6330):77-79; 1991.
109. Le Ber, I.; Camuzat, A.; Castelnovo, G.; Azulay, J. P.; Genton, P.; Gastaut, J. L.; Broglin, D.; Labauge, P.; Brice, A.; Durr, A. Prevalence of dentatorubral-pallidoluysian atrophy in a large series of white patients with cerebellar ataxia. Arch. Neurol. 60(8):1097-1099; 2003.
110. Lee, I. H.; Soong, B. W.; Lu, Y. C.; Chang, Y. C. Dentatorubropallidoluysian atrophy in Chinese. Arch. Neurol. 58(11):1905-1908; 2001.
111. Lee, J. S.; Hong, J. M.; Moon, G. J.; Lee, P. H.; Ahn, Y. H.; Bang, O. Y. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells 28(6):1099-1106; 2010.
112. Lee, P. H.; Kim, J. W.; Bang, O. Y.; Ahn, Y. H.; Joo, I. S.; Huh, K. Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin. Pharmacol. Ther. 83(5):723-730; 2008.
113. Lehky, T. J.; Chen, C. J.; di Prospero, N. A.; Rhodes, L. E.; Fischbeck, K.; Floeter, M. K. Standard and modified statistical MUNE evaluations in spinal-bulbar muscular atrophy. Muscle Nerve 40(5):809-814; 2009.
114. Li, S. H.; Li, X. J. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet. 20(3):146-154; 2004.
115. Liu, J.; Tang, T. S.; Tu, H.; Nelson, O.; Herndon, E.; Huynh, D. P.; Pulst, S. M.; Bezprozvanny, I. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2. J. Neurosci. 29(29):9148-9162; 2009.
116. Lund, A.; Udd, B.; Juvonen, V.; Andersen, P. M.; Cederquist, K.; Davis, M.; Gellera, C.; Kolmel, C.; Ronnevi, L. O.; Sperfeld, A. D.; Sorensen, S. A.; Tranebjaerg, L.; Van, M. L.; Watanabe, M.; Weber, M.; Yeung, L.; Savontaus, M. L. Multiple founder effects in spinal and bulbar muscular atrophy (SBMA, Kennedy disease) around the world. Eur. J. Hum. Genet. 9(6):431-436; 2001.
117. Mader, I.; Karitzky, J.; Klose, U.; Seeger, U.; Sperfeld, A.; Naegele, T.; Schick, F.; Ludolph, A.; Grodd, W. Proton MRS in Kennedy disease: Absolute metabolite and macromolecular concentrations. J. Magn. Reson. Imaging 16(2): 160-167; 2002.
118. Manganelli, F.; Perretti, A.; Nolano, M.; Lanzillo, B.; Bruni, A. C.; De Michele, G.; Filla, A.; Santoro, L. Electrophysiologic characterization in spinocerebellar ataxia 17. Neurology 66(6):932-934; 2006.
119. Mangiarini, L.; Sathasivam, K.; Seller, M.; Cozens, B.; Harper, A.; Hetherington, C.; Lawton, M.; Trottier, Y.; Lehrach, H.; Davies, S. W.; Bates, G. P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87(3):493-506; 1996.
120. Manto, M. U. The wide spectrum of spinocerebellar ataxias (SCAs). Cerebellum 4(1):2-6; 2005.
121. Mareschi, K.; Novara, M.; Rustichelli, D.; Ferrero, I.; Guido, D.; Carbone, E.; Medico, E.; Madon, E.; Vercelli, A.; Fagioli, F. Neural differentiation of human mesenchymal stem cells: Evidence for expression of neural markers and eag K+ channel types. Exp. Hematol. 34(11):1563-1572; 2006.
122. Margulis, B. A.; Vigont, V.; Lazarev, V. F.; Kaznacheyeva, E. V.; Guzhova, I. V. Pharmacological protein targets in polyglutamine diseases: Mutant polypeptides and their interactors. FEBS Lett. 587(13):1997-2007; 2013.
123. Marmont, A. M.; Gualandi, F.; Piaggio, G.; Podesta, M.; Teresa van Lint, M.; Bacigalupo, A.; Nobili, F. Allogeneic bone marrow transplantation (BMT) for refractory Behcet's disease with severe CNS involvement. Bone Marrow Transplant. 37(11):1061-1063; 2006.
124. Martin, J. B.; Gusella, J. F. Huntington's disease. Pathogenesis and management. N. Engl. J. Med. 315(20):1267-1276; 1986.
125. Martins, S.; Matama, T.; Guimaraes, L.; Vale, J.; Guimaraes, J.; Ramos, L.; Coutinho, P.; Sequeiros, J.; Silveira, I. Portuguese families with dentatorubropallidoluysian atrophy (DRPLA) share a common haplotype of Asian origin. Eur. J. Hum. Genet. 11(10):808-811; 2003.
126. Matilla-Duenas, A.; Goold, R.; Giunti, P. Clinical, genetic, molecular, and pathophysiological insights into spinocerebellar ataxia type 1. Cerebellum 7(2):106-114; 2008.
127. Mazzini, L.; Ferrero, I.; Luparello, V.; Rustichelli, D.; Gunetti, M.; Mareschi, K.; Testa, L.; Stecco, A.; Tarletti, R.; Miglioretti, M.; Fava, E.; Nasuelli, N.; Cisari, C.; Massara, M.; Vercelli, R.; Oggioni, G. D.; Carriero, A.; Cantello, R.; Monaco, F.; Fagioli, F. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial. Exp. Neurol. 223(1):229-237; 2010.
128. McNeil, S. M.; Novelletto, A.; Srinidhi, J.; Barnes, G.; Kornbluth, I.; Altherr, M. R.; Wasmuth, J. J.; Gusella, J. F.; MacDonald, M. E.; Myers, R. H. Reduced penetrance of the Huntington's disease mutation. Hum. Mol. Genet. 6(5):775-779; 1997.
129. Menzies, F. M.; Huebener, J.; Renna, M.; Bonin, M.; Riess, O.; Rubinsztein, D. C. Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3. Brain 133(Pt 1):93-104; 2010.
130. Metcalf, D. J.; Garcia-Arencibia, M.; Hochfeld, W. E.; Rubinsztein, D. C. Autophagy and misfolded proteins in neurodegeneration. Exp. Neurol. 238(1):22-28; 2012.
131. Mirowska-Guzel, D.; Seniow, J.; Sulek, A.; Lesniak, M.; Czlonkowska, A. Are cognitive and behavioural deficits a part of the clinical picture in Kennedy's disease? A case study. Neurocase 15(4):332-337; 2009.
132. Muchowski, P. J.; Ning, K.; D'Souza-Schorey, C.; Fields, S. Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment. Proc. Natl. Acad. Sci. USA 99(2): 727-732; 2002.
133. Mueller, D.; Shamblott, M. J.; Fox, H. E.; Gearhart, J. D.; Martin, L. J. Transplanted human embryonic germ cellderived neural stem cells replace neurons and oligodendrocytes in the forebrain of neonatal mice with excitotoxic brain damage. J. Neurosci. Res. 82(5):592-608; 2005.
134. Munoz, E.; Campdelacreu, J.; Ferrer, I.; Rey, M. J.; Cardozo, A.; Gomez, B.; Tolosa, E. Severe cerebral white matter involvement in a case of dentatorubropallidoluysian atrophy studied at autopsy. Arch. Neurol. 61(6):946-949; 2004.
135. Nagashima, Y.; Kowa, H.; Tsuji, S.; Iwata, A. FAT10 protein binds to polyglutamine proteins and modulates their solubility. J. Biol. Chem. 286(34):29594-29600; 2011.
136. Naito, H.; Oyanagi, S. Familial myoclonus epilepsy and choreoathetosis: Hereditary dentatorubral-pallidoluysian atrophy. Neurology 32(8):798-807; 1982.
137. Nakamura, K.; Yoshida, K.; Miyazaki, D.; Morita, H.; Ikeda, S. Spinocerebellar ataxia type 6 (SCA6): Clinical pilot trial with gabapentin. J. Neurol. Sci. 278(1-2):107-111; 2009.
138. Nakano, K. K.; Dawson, D. M.; Spence, A. Machado disease. A hereditary ataxia in Portuguese emigrants to Massachusetts. Neurology 22(1):49-55; 1972.
139. Nakashima, K.; Watanabe, Y.; Kusumi, M.; Nanba, E.; Maeoka, Y.; Nakagawa, M.; Igo, M.; Irie, H.; Ishino, H.; Fujimoto, A.; Goto, J.; Takahashi, K. Epidemiological and genetic studies of Huntington's disease in the San-in area of Japan. Neuroepidemiology 15(3):126-131; 1996.
140. Nasir, J.; Floresco, S. B.; O'Kusky, J. R.; Diewert, V. M.; Richman, J. M.; Zeisler, J.; Borowski, A.; Marth, J. D.; Phillips, A. G.; Hayden, M. R. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81(5):811-823; 1995.
141. Nihei, Y.; Ito, D.; Okada, Y.; Akamatsu, W.; Yagi, T.; Yoshizaki, T.; Okano, H.; Suzuki, N. Enhanced aggregation of androgen receptor in induced pluripotent stem cellderived neurons from spinal and bulbar muscular atrophy. J. Biol. Chem. 288(12):8043-8052; 2013.
142. Nucifora, Jr., F. C.; Ellerby, L. M.; Wellington, C. L.; Wood, J. D.; Herring, W. J.; Sawa, A.; Hayden, M. R.; Dawson, V. L.; Dawson, T. M.; Ross, C. A. Nuclear localization of a non-caspase truncation product of atrophin-1, with an expanded polyglutamine repeat, increases cellular toxicity. J. Biol. Chem. 278(15):13047-13055; 2003.
143. Okabe, S.; Forsberg-Nilsson, K.; Spiro, A. C.; Segal, M.; McKay, R. D. Development of neuronal precursor cells and functional postmitotic neurons from embryonic stem cells in vitro. Mech. Dev. 59(1):89-102; 1996.
144. Orr, H. T.; Zoghbi, H. Y. Trinucleotide repeat disorders. Annu. Rev. Neurosci. 30:575-621; 2007.
145. Parboosingh, J. S.; Figlewicz, D. A.; Krizus, A.; Meininger, V.; Azad, N. A.; Newman, D. S.; Rouleau, G. A. Spinobulbar muscular atrophy can mimic ALS: The importance of genetic testing in male patients with atypical ALS. Neurology 49(2):568-572; 1997.
146. Park, I. H.; Arora, N.; Huo, H.; Maherali, N.; Ahfeldt, T.; Shimamura, A.; Lensch, M. W.; Cowan, C.; Hochedlinger, K.; Daley, G. Q. Disease-specific induced pluripotent stem cells. Cell 34(5):877-886; 2008.
147. Pavoni, M.; Granieri, E.; Govoni, V.; Pavoni, V.; Del Senno, L.; Mapelli, G. Epidemiologic approach to Huntington's disease in northern Italy (Ferrara area). Neuroepidemiology 9(6):306-314; 1990.
148. Potter, N. T.; Meyer, M. A.; Zimmerman, A. W.; Eisenstadt, M. L.; Anderson, I. J. Molecular and clinical findings in a family with dentatorubral-pallidoluysian atrophy. Ann. Neurol. 37(2):273-277; 1995.
149. Ramos-Arroyo, M. A.; Moreno, S.; Valiente, A. Incidence and mutation rates of Huntington's disease in Spain: Experience of 9 years of direct genetic testing. J. Neurol. Neurosurg. Psychiatry 76(3):337-342; 2005.
150. Raoul, C.; Abbas-Terki, T.; Bensadoun, J. C.; Guillot, S.; Haase, G.; Szulc, J.; Henderson, C. E.; Aebischer, P. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat. Med. 11(4):423-428; 2005.
151. Reddy, P. H.; Williams, M.; Charles, V.; Garrett, L.; Pike-Buchanan, L.; Whetsell, Jr., W. O.; Miller, G.; Tagle, D. A. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat. Genet. 20(2):198-202; 1998.
152. Reubinoff, B. E.; Pera, M. F.; Fong, C. Y.; Trounson, A.; Bongso, A. Embryonic stem cell lines from human blastocysts: Somatic differentiation in vitro. Nat. Biotechnol. 18(4):399-404; 2000.
153. Reuter, I.; Tai, Y. F.; Pavese, N.; Chaudhuri, K.R.; Mason, S.; Polkey, C. E.; Clough, C.; Brooks, D. J.; Barker, R. A.; Piccini, P. Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease. J. Neurol. Neurosurg. Psychiatry 79(8):948-951; 2008.
154. Reynolds, B. A.; Tetzlaff, W.; Weiss, S. A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes. J. Neurosci. 12(11):4565-4574; 1992.
155. Rocchi, C.; Greco, V.; Urbani, A.; Di, G. A.; Priori, M.; Massa, R.; Bernardi, G.; Marfia, G. A. Subclinical autonomic dysfunction in spinobulbar muscular atrophy (Kennedy disease). Muscle Nerve 44(5):737-740; 2011.
156. Rolfs, A.; Koeppen, A. H.; Bauer, I.; Bauer, P.; Buhlmann, S.; Topka, H.; Schols, L.; Riess, O. Clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17). Ann. Neurol. 54(3):367-375; 2003.
157. Romanul, F. C.; Fowler, H. L.; Radvany, J.; Feldman, R. G.; Feingold, M. Azorean disease of the nervous system. N. Engl. J. Med. 296(26):1505-1508; 1977.
158. Roos, R. A. Huntington's disease: A clinical review. Orphanet J. Rare. Dis. 5(1):40; 2010.
159. Roscic, A.; Baldo, B.; Crochemore, C.; Marcellin, D.; Paganetti, P. Induction of autophagy with catalytic mTOR inhibitors reduces huntingtin aggregates in a neuronal cell model. J. Neurochem. 119(2):398-407; 2011.
160. Rosenberg, R. N.; Nyhan, W. L.; Bay, C.; Shore, P. Autosomal dominant striatonigral degeneration. A clinical, pathologic, and biochemical study of a new genetic disorder. Neurology 26(8):703-714; 1976.
161. Rosenblatt, A.; Abbott, M. H.; Gourley, L. M.; Troncoso, J. C.; Margolis, R. L.; Brandt, J.; Ross, C. A. Predictors of neuropathological severity in 100 patients with Huntington's disease. Ann. Neurol. 54(4):488-493; 2003.
162. Ross, C. A.; Tabrizi, S. J. Huntington's disease: From molecular pathogenesis to clinical treatment. Lancet Neurol. 10(1):83-98; 2011.
163. Rosser, A. E.; Tyers, P.; Dunnett, S. B. The morphological development of neurons derived from EGF-and FGF-2-driven human CNS precursors depends on their site of integration in the neonatal rat brain. Eur. J. Neurosci. 12(7):2405-2413; 2000.
164. Rub, U.; Brunt, E. R.; Deller, T. New insights into the pathoanatomy of spinocerebellar ataxia type 3 (Machado-Joseph disease). Curr. Opin. Neurol. 21(2):111-116; 2008.
165. Rub, U.; Schols, L.; Paulson, H.; Auburger, G.; Kermer, P.; Jen, J. C.; Seidel, K.; Korf, H. W.; Deller, T. Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7. Prog. Neurobiol. 104:38-66; 2013.
166. Rufa, A.; Dotti, M. T.; Galli, L.; Orrico, A.; Sicurelli, F.; Federico, A. Spinocerebellar ataxia type 2 (SCA2) associated with retinal pigmentary degeneration. Eur. Neurol. 47(2):128-129; 2002.
167. Sakahira, H.; Breuer, P.; Hayer-Hartl, M. K.; Hartl, F. U. Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity. Proc. Natl. Acad. Sci. USA 99(Suppl 4):16412-16418; 2002.
168. Sakai, K.; Yamada, M.; Sato, T.; Yamada, M.; Tsuji, S.; Takahashi, H. Neuronal atrophy and synaptic alteration in a mouse model of dentatorubral-pallidoluysian atrophy. Brain 129(Pt 9):2353-2362; 2006.
169. Sasaki, H.; Fukazawa, T.; Yanagihara, T.; Hamada, T.; Shima, K.; Matsumoto, A.; Hashimoto, K.; Ito, N.; Wakisaka, A.; Tashiro, K. Clinical features and natural history of spinocerebellar ataxia type 1. Acta Neurol. Scand. 93(1):64-71; 1996.
170. Sato, T.; Miura, M.; Yamada, M.; Yoshida, T.; Wood, J. D.; Yazawa, I.; Masuda, M.; Suzuki, T.; Shin, R. M.; Yau, H. J.; Liu, F. C.; Shimohata, T.; Onodera, O.; Ross, C. A.; Katsuki, M.; Takahashi, H.; Kano, M.; Aosaki, T.; Tsuji, S. Severe neurological phenotypes of Q129 DRPLA transgenic mice serendipitously created by en masse expansion of CAG repeats in Q76 DRPLA mice. Hum. Mol. Genet. 18(4):723-736; 2009.
171. Sato, T.; Oyake, M.; Nakamura, K.; Nakao, K.; Fukusima, Y.; Onodera, O.; Igarashi, S.; Takano, H.; Kikugawa, K.; Ishida, Y.; Shimohata, T.; Koide, R.; Ikeuchi, T.; Tanaka, H.; Futamura, N.; Matsumura, R.; Takayanagi, T.; Tanaka, F.; Sobue, G.; Komure, O.; Takahashi, M.; Sano, A.; Ichikawa, Y.; Goto, J.; Kanazawa, I.; Katsuki, M.; Tsuji, S. Transgenic mice harboring a full-length human mutant DRPLA gene exhibit age-dependent intergenerational and somatic instabilities of CAG repeats comparable with those in DRPLA patients. Hum. Mol. Genet. 8(1):99-106; 1999.
172. Schilling, G.; Wood, J. D.; Duan, K.; Slunt, H. H.; Gonzales, V.; Yamada, M.; Cooper, J. K.; Margolis, R. L.; Jenkins, N. A.; Copeland, N. G.; Takahashi, H.; Tsuji, S.; Price, D. L.; Borchelt, D. R.; Ross, C. A. Nuclear accumulation of truncated atrophin-1 fragments in a transgenic mouse model of DRPLA. Neuron 24(1):275-286; 1999.
173. Schmidt, B. J.; Greenberg, C. R.; Allingham-Hawkins, D. J.; Spriggs, E. L. Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology 59(5):770-772; 2002.
174. Schols, L.; Bauer, P.; Schmidt, T.; Schulte, T.; Riess, O. Autosomal dominant cerebellar ataxias: Clinical features, genetics, and pathogenesis. Lancet Neurol. 3(5):291-304; 2004.
175. Schulz, J. B.; Borkert, J.; Wolf, S.; Schmitz-Hubsch, T.; Rakowicz, M.; Mariotti, C.; Schols, L.; Timmann, D.; van de Warrenburg, B.; Durr, A.; Pandolfo, M.; Kang, J. S.; Mandly, A. G.; Nagele, T.; Grisoli, M.; Boguslawska, R.; Bauer, P.; Klockgether, T.; Hauser, T. K. Visualization, quantification and correlation of brain atrophy with clinical symptoms in spinocerebellar ataxia types 1, 3 and 6. Neuroimage 49(1):158-168; 2010.
176. Seo, H.; Sonntag, K. C.; Kim, W.; Cattaneo, E.; Isacson, O. Proteasome activator enhances survival of Huntington's disease neuronal model cells. PLoS One 2(2):e238; 2007.
177. Seriola, A.; Spits, C.; Simard, J. P.; Hilven, P.; Haentjens, P.; Pearson, C. E.; Sermon, K. Huntington's and myotonic dystrophy hESCs: Down-regulated trinucleotide repeat instability and mismatch repair machinery expression upon differentiation. Hum. Mol. Genet. 20(1):176-185; 2011.
178. Shamblott, M. J.; Axelman, J.; Wang, S.; Bugg, E. M.; Littlefield, J. W.; Donovan, P. J.; Blumenthal, P. D.; Huggins, G. R.; Gearhart, J. D. Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc. Natl. Acad. Sci. USA 95(23):13726-13731; 1998.
179. Shimohata, T.; Nakajima, T.; Yamada, M.; Uchida, C.; Onodera, O.; Naruse, S.; Kimura, T.; Koide, R.; Nozaki, K.; Sano, Y.; Ishiguro, H.; Sakoe, K.; Ooshima, T.; Sato, A.; Ikeuchi, T.; Oyake, M.; Sato, T.; Aoyagi, Y.; Hozumi, I.; Nagatsu, T.; Takiyama, Y.; Nishizawa, M.; Goto, J.; Kanazawa, I.; Davidson, I.; Tanese, N.; Takahashi, H.; Tsuji, S. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat. Genet. 26(1):29-36; 2000.
180. Shiwach, R. S.; Lindenbaum, R. H. Prevalence of Huntington's disease among UK immigrants from the Indian subcontinent. Br. J. Psychiatry 157:598-599; 1990.
181. Shoulson, I.; Young, A. B. Milestones in Huntington disease. Mov. Disord. 26(6):1127-1133; 2011.
182. Sinclair, R.; Greenland, K. J.; Egmond, S.; Hoedemaker, C.; Chapman, A.; Zajac, J. D. Men with Kennedy disease have a reduced risk of androgenetic alopecia. Br. J. Dermatol. 157(2):290-294; 2007.
183. Smith, J. K.; Gonda, V. E.; Malamud, N. Unusual form of cerebellar ataxia: Combined dentato-rubral and pallido-Luysian degeneration. Neurology 8(3):205-209; 1958.
184. Sobue, G.; Doyu, M.; Kachi, T.; Yasuda, T.; Mukai, E.; Kumagai, T.; Mitsuma, T. Subclinical phenotypic expressions in heterozygous females of X-linked recessive bulbospinal neuronopathy. J. Neurol. Sci. 117(1-2):74-78; 1993.
185. Sobue, G.; Hashizume, Y.; Mukai, E.; Hirayama, M.; Mitsuma, T.; Takahashi, A. X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain 112(Pt 1):209-232; 1989.
186. Solans, A.; Zambrano, A.; Rodriguez, M.; Barrientos, A. Cytotoxicity of a mutant huntingtin fragment in yeast involves early alterations in mitochondrial OXPHOS complexes II and III. Hum. Mol. Genet. 15(20):3063-3081; 2006.
187. Soldner, F.; Hockemeyer, D.; Beard, C.; Gao, Q.; Bell, G. W.; Cook, E. G.; Hargus, G.; Blak, A.; Cooper, O.; Mitalipova, M.; Isacson, O.; Jaenisch, R. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136(5):964-977; 2009.
188. Soong, B. W.; Liu, R. S. Positron emission tomography in asymptomatic gene carriers of Machado-Joseph disease. J. Neurol. Neurosurg. Psychiatry 64(4):499-504; 1998.
189. Sperfeld, A. D.; Hanemann, C. O.; Ludolph, A. C.; Kassubek, J. Laryngospasm: An underdiagnosed symptom of X-linked spinobulbar muscular atrophy. Neurology 64(4):753-754; 2005.
190. Sperfeld, A. D.; Karitzky, J.; Brummer, D.; Schreiber, H.; Haussler, J.; Ludolph, A. C.; Hanemann, C. O. X-linked bulbospinal neuronopathy: Kennedy disease. Arch. Neurol. 59(12):1921-1926; 2002.
191. Steffan, J. S.; Kazantsev, A.; Spasic-Boskovic, O.; Greenwald, M.; Zhu, Y. Z.; Gohler, H.; Wanker, E. E.; Bates, G. P.; Housman, D. E.; Thompson, L. M. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA 97(12):6763-6768; 2000.
192. Stevanin, G.; Brice, A. Spinocerebellar ataxia 17 (SCA17) and Huntington's disease-like 4 (HDL4). Cerebellum 7(2): 170-178; 2008.
193. Stevanin, G.; Durr, A.; David, G.; Didierjean, O.; Cancel, G.; Rivaud, S.; Tourbah, A.; Warter, J. M.; Agid, Y.; Brice, A. Clinical and molecular features of spinocerebellar ataxia type 6. Neurology 49(5):1243-1246; 1997.
194. Sudarsky, L.; Coutinho, P. Machado-Joseph disease. Clin. Neurosci. 3(1):17-22; 1995.
195. Sugars, K. L.; Rubinsztein, D. C. Transcriptional abnormalities in Huntington disease. Trends Genet. 19(5):233-238; 2003.
196. Suzuki, K.; Katsuno, M.; Banno, H.; Takeuchi, Y.; Atsuta, N.; Ito, M.; Watanabe, H.; Yamashita, F.; Hori, N.; Nakamura, T.; Hirayama, M.; Tanaka, F.; Sobue, G. CAG repeat size correlates to electrophysiological motor and sensory phenotypes in SBMA. Brain 131(Pt 1):229-239; 2008.
197. Svendsen, C. N.; Caldwell, M. A.; Shen, J.; ter Borg, M. G.; Rosser, A. E.; Tyers, P.; Karmiol, S.; Dunnett, S. B. Long-term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson's disease. Exp. Neurol. 148(1):135-146; 1997.
198. Takano, H.; Cancel, G.; Ikeuchi, T.; Lorenzetti, D.; Mawad, R.; Stevanin, G.; Didierjean, O.; Durr, A.; Oyake, M.; Shimohata, T.; Sasaki, R.; Koide, R.; Igarashi, S.; Hayashi, S.; Takiyama, Y.; Nishizawa, M.; Tanaka, H.; Zoghbi, H.; Brice, A.; Tsuji, S. Close associations between prevalences of dominantly inherited spinocerebellar ataxias with CAG-repeat expansions and frequencies of large normal CAG alleles in Japanese and Caucasian populations. Am. J. Hum. Genet. 63(4):1060-1066; 1998.
199. Tanaka, F.; Katsuno, M.; Banno, H.; Suzuki, K.; Adachi, H.; Sobue, G. Current status of treatment of spinal and bulbar muscular atrophy. Neural Plast. 2012:369284; 2012.
200. Tanaka, M.; Machida, Y.; Niu, S.; Ikeda, T.; Jana, N. R.; Doi, H.; Kurosawa, M.; Nekooki, M.; Nukina, N. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat. Med. 10(2):148-154; 2004.
201. Tang, B.; Liu, C.; Shen, L.; Dai, H.; Pan, Q.; Jing, L.; Ouyang, S.; Xia, J. Frequency of SCA1, SCA2, SCA3/ MJD, SCA6, SCA7, and DRPLA CAG trinucleotide repeat expansion in patients with hereditary spinocerebellar ataxia from Chinese kindreds. Arch. Neurol. 57(4): 540-544; 2000.
202. Taylor, J. P.; Hardy, J.; Fischbeck, K. H. Toxic proteins in neurodegenerative disease. Science 296(5575):1991-1995; 2002.
203. The HD iPSC Consortium. Induced pluripotent stem cells from patients with Huntington's disease show CAGrepeat-expansion-associated phenotypes. Cell Stem Cell 11(2):264-278; 2012.
204. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72(6):971-983; 1993.
205. Thomson, J. A.; Itskovitz-Eldor, J.; Shapiro, S. S.; Waknitz, M. A.; Swiergiel, J. J.; Marshall, V. S.; Jones, J. M. Embryonic stem cell lines derived from human blastocysts. Science 282(5391):1145-1147; 1998.
206. Tsai, Y. C.; Fishman, P. S.; Thakor, N. V.; Oyler, G. A. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J. Biol. Chem. 278(24):22044-22055; 2003.
207. Tsuji, S.; Onodera, O.; Goto, J.; Nishizawa, M. Sporadic ataxias in Japan-A population-based epidemiological study. Cerebellum 7(2):189-197; 2008.
208. Turnpenny, L.; Brickwood, S.; Spalluto, C. M.; Piper, K.; Cameron, I. T.; Wilson, D. I.; Hanley, N. A. Derivation of human embryonic germ cells: An alternative source of pluripotent stem cells. Stem Cells 21(5):598-609; 2003.
209. Udd, B.; Holmgren, G. [X-linked recessive spinal and bulbar muscular atrophy. Kennedy syndrome]. Duodecim 112(3):218-219; 1996.
210. Vater, C.; Kasten, P.; Stiehler, M. Culture media for the differentiation of mesenchymal stromal cells. Acta Biomater. 7(2):463-477; 2011.
211. Venkataramana, N. K.; Kumar, S. K.; Balaraju, S.; Radhakrishnan, R. C.; Bansal, A.; Dixit, A.; Rao, D. K.; Das, M.; Jan, M.; Gupta, P. K.; Totey, S. M. Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease. Transl. Res. 155(2):62-70; 2010.
212. Vierbuchen, T.; Ostermeier, A.; Pang, Z. P.; Kokubu, Y.; Sudhof, T. C.; Wernig, M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463(7284):1035-1041; 2010.
213. Vonsattel, J. P.; DiFiglia, M. Huntington disease. J. Neuropathol. Exp. Neurol. 57(5):369-384; 1998.
214. Walker, F. O. Huntington's disease. Lancet 369(9557):218-228; 2007.
215. Wang, Y. G.; Du, J.; Wang, J. L.; Chen, J.; Chen, C.; Luo, Y. Y.; Xiao, Z. Q.; Jiang, H.; Yan, X. X.; Xia, K.; Pan, Q.; Tang, B. S.; Shen, L. Six cases of SCA3/MJD patients that mimic hereditary spastic paraplegia in clinic. J. Neurol. Sci. 285(1-2):121-124; 2009.
216. Watase, K.; Gatchel, J. R.; Sun, Y.; Emamian, E.; Atkinson, R.; Richman, R.; Mizusawa, H.; Orr, H. T.; Shaw, C.; Zoghbi, H. Y. Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med. 4(5):e182; 2007.
217. Waza, M.; Adachi, H.; Katsuno, M.; Minamiyama, M.; Sang, C.; Tanaka, F.; Inukai, A.; Doyu, M.; Sobue, G. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutaminemediated motor neuron degeneration. Nat. Med. 11(10): 1088-1095; 2005.
218. Wichterle, H.; Lieberam, I.; Porter, J. A.; Jessell, T. M. Directed differentiation of embryonic stem cells into motor neurons. Cell 110(3):385-397; 2002.
219. Wilburn, B.; Rudnicki, D. D.; Zhao, J.; Weitz, T. M.; Cheng, Y.; Gu, X.; Greiner, E.; Park, C. S.; Wang, N.; Sopher, B. L.; La Spada, A. R.; Osmand, A.; Margolis, R. L.; Sun, Y. E.; Yang, X. W. An antisense CAG repeat transcript at JPH3 locus mediates expanded polyglutamine protein toxicity in Huntington's disease-like 2 mice. Neuron 70(3):427-440; 2011.
220. Woods, B. T.; Schaumburg, H. H. Nigro-spino-dentatal degeneration with nuclear ophthalmoplegia. A unique and partially treatable clinico-pathological entity. J. Neurol. Sci. 17(2):149-166; 1972.
221. Wu, Y. R.; Lin, H. Y.; Chen, C. M.; Gwinn-Hardy, K.; Ro, L. S.; Wang, Y. C.; Li, S. H.; Hwang, J. C.; Fang, K.; Hsieh-Li, H. M.; Li, M. L.; Tung, L. C.; Su, M. T.; Lu, K. T.; Lee-Chen, G. J. Genetic testing in spinocerebellar ataxia in Taiwan: Expansions of trinucleotide repeats in SCA8 and SCA17 are associated with typical Parkinson's disease. Clin. Genet. 65(3):209-214; 2004.
222. Wullner, U.; Reimold, M.; Abele, M.; Burk, K.; Minnerop, M.; Dohmen, B. M.; Machulla, H. J.; Bares, R.; Klockgether, T. Dopamine transporter positron emission tomography in spinocerebellar ataxias type 1, 2, 3, and 6. Arch. Neurol. 62(8):1280-1285; 2005.
223. Yamada, M.; Sato, T.; Tsuji, S.; Takahashi, H. CAG repeat disorder models and human neuropathology: Similarities and differences. Acta Neuropathol. 115(1):71-86; 2008.
224. Yamada, M.; Tan, C. F.; Inenaga, C.; Tsuji, S.; Takahashi, H. Sharing of polyglutamine localization by the neuronal nucleus and cytoplasm in CAG-repeat diseases. Neuropathol. Appl. Neurobiol. 30(6):665-675; 2004.
225. Yamada, M.; Wood, J. D.; Shimohata, T.; Hayashi, S.; Tsuji, S.; Ross, C. A.; Takahashi, H. Widespread occurrence of intranuclear atrophin-1 accumulation in the central nervous system neurons of patients with dentatorubral-pallidoluysian atrophy. Ann. Neurol. 49(1):14-23; 2001.
226. Yanagisawa, H.; Fujii, K.; Nagafuchi, S.; Nakahori, Y.; Nakagome, Y.; Akane, A.; Nakamura, M.; Sano, A.; Komure, O.; Kondo, I.; Jin, D. K.; Sorensen, S. A.; Potter, N. T.; Young, S. R.; Nakamura, K.; Nukina, N.; Nagao, Y.; Tadokoro, K.; Okuyama, T.; Miyashita, T.; Inoue, T.; Kanazawa, I.; Yamada, M. A unique origin and multistep process for the generation of expanded DRPLA triplet repeats. Hum. Mol. Genet. 5(3):373-379; 1996.
227. Yazawa, I.; Hazeki, N.; Kanazawa, I. Expanded glutamine repeat enhances complex formation of dentatorubral-pallidoluysian atrophy (DRPLA) protein in human brains. Biochem. Biophys. Res. Commun. 250(1):22-26; 1998.
228. Yazawa, I.; Nukina, N.; Hashida, H.; Goto, J.; Yamada, M.; Kanazawa, I. Abnormal gene product identified in hereditary dentatorubral-pallidoluysian atrophy (DRPLA) brain. Nat. Genet. 10(1):99-103; 1995.
229. Ying, M.; Xu, R.; Wu, X.; Zhu, H.; Zhuang, Y.; Han, M.; Xu, T. Sodium butyrate ameliorates histone hypoacetylation and neurodegenerative phenotypes in a mouse model for DRPLA. J. Biol. Chem. 281(18):12580-12586; 2006.
230. Yoo, S. Y.; Pennesi, M. E.; Weeber, E. J.; Xu, B.; Atkinson, R.; Chen, S.; Armstrong, D. L.; Wu, S. M.; Sweatt, J. D.; Zoghbi, H. Y. SCA7 knockin mice model human SCA7 and reveal gradual accumulation of mutant ataxin-7 in neurons and abnormalities in short-term plasticity. Neuron 37(3):383-401; 2003.
231. Yu, J.; Vodyanik, M. A.; Smuga-Otto, K.; Ntosiewicz-Bourget, J.; Frane, J. L.; Tian, S.; Nie, J.; Jonsdottir, G. A.; Ruotti, V.; Stewart, R.; Slukvin, I. I.; Thomson, J. A. Induced pluripotent stem cell lines derived from human somatic cells. Science 318(5858):1917-1920; 2007.
232. Yvert, G.; Lindenberg, K. S.; Picaud, S.; Landwehrmeyer, G. B.; Sahel, J. A.; Mandel, J. L. Expanded polyglutamines induce neurodegeneration and trans-neuronal alterations in cerebellum and retina of SCA7 transgenic mice. Hum. Mol. Genet. 9(17):2491-2506; 2000.
233. Zeitlin, S.; Liu, J. P.; Chapman, D. L.; Papaioannou, V. E.; Efstratiadis, A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat. Genet. 11(2):155-163; 1995.
234. Zhuchenko, O.; Bailey, J.; Bonnen, P.; Ashizawa, T.; Stockton, D. W.; Amos, C.; Dobyns, W. B.; Subramony, S. H.; Zoghbi, H. Y.; Lee, C. C. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat. Genet. 15(1):62-69; 1997.
235. Zoghbi, H. Y.; Orr, H. T. Polyglutamine diseases: Protein cleavage and aggregation. Curr. Opin. Neurobiol. 9(5): 566-570; 1999.
236. Zuccato, C.; Valenza, M.; Cattaneo, E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev. 90(3):905-981; 2010.